FibroGen CEO resigns after back-to-back drug study failures, job cuts


The CEO oversaw the company through its first FDA drug approval and the Covid-19 pandemic.

Previous Lazydays continues national expansion with Knoxville acquisition
Next Biogen to cut another 1,000 jobs in 'complete redesign'